BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15377848)

  • 1. Mutations of the p53 gene and loss of heterozygosity at chromosome 17p13.1 are associated with increased survivin expression in breast cancer.
    Tsuji N; Furuse K; Asanuma K; Furuya M; Kondoh K; Kamagata C; Sasaki M; Kobayashi D; Yagihashi A; Takahashi H; Watanabe N
    Breast Cancer Res Treat; 2004 Sep; 87(1):23-31. PubMed ID: 15377848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas.
    Byun DS; Cho K; Ryu BK; Lee MG; Kang MJ; Kim HR; Chi SG
    Cancer Res; 2003 Nov; 63(21):7068-75. PubMed ID: 14612497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer.
    Nakano J; Huang CL; Liu D; Ueno M; Sumitomo S; Yokomise H
    Int J Oncol; 2005 Nov; 27(5):1215-21. PubMed ID: 16211215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity.
    Libè R; Groussin L; Tissier F; Elie C; René-Corail F; Fratticci A; Jullian E; Beck-Peccoz P; Bertagna X; Gicquel C; Bertherat J
    Clin Cancer Res; 2007 Feb; 13(3):844-50. PubMed ID: 17289876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas.
    Boidot R; Vegran F; Jacob D; Chevrier S; Gangneux N; Taboureau J; Oudin C; Rainville V; Mercier L; Lizard-Nacol S
    Genes Chromosomes Cancer; 2008 Apr; 47(4):299-308. PubMed ID: 18181175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer.
    Végran F; Boidot R; Oudin C; Defrain C; Rebucci M; Lizard-Nacol S
    Oncogene; 2007 Jan; 26(2):290-7. PubMed ID: 16847456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
    Mirza A; McGuirk M; Hockenberry TN; Wu Q; Ashar H; Black S; Wen SF; Wang L; Kirschmeier P; Bishop WR; Nielsen LL; Pickett CB; Liu S
    Oncogene; 2002 Apr; 21(17):2613-22. PubMed ID: 11965534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
    Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
    Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.
    Nicoll G; Crichton DN; McDowell HE; Kernohan N; Hupp TR; Thompson AM
    Br J Cancer; 2001 Dec; 85(12):1878-82. PubMed ID: 11747329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detailed deletion mapping in sporadic breast cancer at chromosomal region 17p13 distal to the TP53 gene: association with clinicopathological parameters.
    Seitz S; Poppe K; Fischer J; Nothnagel A; Estévez-Schwarz L; Haensch W; Schlag PM; Scherneck S
    J Pathol; 2001 Jul; 194(3):318-26. PubMed ID: 11439364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific adenovirus-mediated PUMA gene transfer using the survivin promoter enhances radiosensitivity of breast cancer cells in vitro and in vivo.
    Wang R; Wang X; Li B; Lin F; Dong K; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Sep; 117(1):45-54. PubMed ID: 18791823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct expression of Survivin splice variants in breast carcinomas.
    Vegran F; Boidot R; Oudin C; Riedinger JM; Lizard-Nacol S
    Int J Oncol; 2005 Oct; 27(4):1151-7. PubMed ID: 16142334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of loss of heterozygosity at loci on chromosome 17p13.3-ter in sporadic breast cancer is evidence for a putative tumour suppressor gene.
    Liscia DS; Morizio R; Venesio T; Palenzona C; Donadio M; Callahan R
    Br J Cancer; 1999 May; 80(5-6):821-6. PubMed ID: 10360661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
    Eiriksdottir G; Barkardottir RB; Agnarsson BA; Johannesdottir G; Olafsdottir K; Egilsson V; Ingvarsson S
    Oncogene; 1998 Jan; 16(1):21-6. PubMed ID: 9467939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct promoter usage of mdm2 gene in human breast cancer.
    Okumura N; Saji S; Eguchi H; Nakashima S; Saji S; Hayashi S
    Oncol Rep; 2002; 9(3):557-63. PubMed ID: 11956627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity of a locus on 17p13.3, independent of p53, is associated with higher grades of astrocytic tumours.
    Chattopadhyay P; Rathore A; Mathur M; Sarkar C; Mahapatra AK; Sinha S
    Oncogene; 1997 Aug; 15(7):871-4. PubMed ID: 9266974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apoptosis gene signature of Survivin and its splice variant expression in breast carcinoma.
    Végran F; Boidot R; Bonnetain F; Cadouot M; Chevrier S; Lizard-Nacol S
    Endocr Relat Cancer; 2011 Dec; 18(6):783-92. PubMed ID: 21878572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of {gamma}-aminobutyric acid type A receptor-associated protein, a novel tumor suppressor, showing reduced expression in breast cancer.
    Klebig C; Seitz S; Arnold W; Deutschmann N; Pacyna-Gengelbach M; Scherneck S; Petersen I
    Cancer Res; 2005 Jan; 65(2):394-400. PubMed ID: 15695379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.